Industry News

Industry News

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with...

Admin - September 21, 2021

Industry News

AUA2021 Presentation Highlights Results from a Phase 1/2 Clinical Trial of Intramural/Intravesical NanoDoce® Suspension in High-Risk Nonmuscle Invasive Bladder Cancer

FORT WORTH, Texas--(BUSINESS WIRE)--NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that initial results from a Phase 1/2 clinical trial of intramural/intravesical...

Admin - September 21, 2021

Industry News

Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform

BASEL, Switzerland & MONTRÉAL & AUSTIN, Texas--(BUSINESS WIRE)--Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira's investigational T-cell...

Admin - September 21, 2021

Industry News

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

FOSTER CITY, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced that the companies have entered into...

Admin - September 21, 2021

Industry News

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches

INGELHEIM, Germany & ARLINGTON, Texas--(BUSINESS WIRE)--Boehringer Ingelheim today announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the...

Admin - September 21, 2021

Industry News

Infinity BiologiX, Cytox, and Vanguard Pharma Announce the US Launch of the First, Physician Use Only, Polygenic Test to Predict the Risk of Cognitive...

PISCATAWAY, N.J. & OXFORD, England & MANCHESTER, England & MAHWAH, N.J.--(BUSINESS WIRE)--Today, Infinity BiologiX, LLC (IBX), Cytox Ltd, and Vanguard Pharma announce the launch...

Admin - September 21, 2021

1 234...309 Page 3 of 309

Recent Articles

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood...

LabGenius Appoints Dr. Didier Landais as Chief Operating Officer

Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries

Taysha Receives Orphan Drug Designation from the European Commission for TSHA-102 for the Treatment of Rett Syndrome

Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine...

Dicerna Announces New Executive Leadership Appointments

Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021

CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications

Vividion Therapeutics Announces Formation of Scientific Advisory Board

Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

AnHeart Therapeutics Announces Formation of Scientific Advisory Board

Peptilogics to Present First-in-Human Phase 1 Clinical Data of PLG0206 at IDWeek 2021